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Summary 1 
AIMS 2 
To evaluate the disposition of metoprolol after oral administration of an immediate and controlled release formulation before 3 
and after Roux-en-Y gastric bypass (RYGB) surgery in the same individuals and to validate a physiologically-based 4 
pharmacokinetic (PBPK) model for predicting oral bioavailability following RYGB. 5 
METHODS 6 
A single-dose pharmacokinetic study of metoprolol tartrate 200 mg immediate release (Lopresor®) and controlled release 7 
(Slow-Lopresor®) was performed in 14 volunteers before and six to eight months after RYGB. The observed data were 8 
compared with predicted results from the PBPK modelling and simulation of metoprolol tartrate immediate and controlled 9 
release formulation before and after RYGB.  10 
RESULTS 11 
After administration of metoprolol immediate and controlled release, no statistically significant difference in the observed 12 
AUC0-24h was shown, although a tendency towards an increased oral exposure could be observed as AUC0-24h was 32.4% 13 
(95% CI [1.36, 63.5]) and 55.9% (95% CI [5.73, 106]) % higher following RYGB for the immediate and controlled release 14 
formulation, respectively. This could be explained by surgery related weight loss and a reduced presystemic 15 
biotransformation in the proximal GI-tract. The PBPK modelling and simulation predicted values were similar to the 16 
observed data, confirming its validity. 17 
CONCLUSIONS 18 
The disposition of metoprolol from an immediate release formulation and a controlled release formulation was not 19 
significantly altered after RYGB; there was a tendency to an increase, which was also predicted by PBPK modelling and 20 
simulation. 21 
22 
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What is known about this subject? 23 
 RYGB has an influence on a number of factors known to govern drug absorption including an increased gastric pH, 24 
delayed inlet of bile acids, and reduced small intestinal surface area. 25 
 There are only a few studies conducted, in which changes in oral drug exposure after RYGB have been observed. 26 
What this study adds to our knowledge? 27 
 The disposition of metoprolol was not significantly different post-RYGB, although a tendency to a higher exposure 28 
was seen. 29 
 The disposition of metoprolol controlled release remained unaltered following RYGB.  30 
 The study added to the body of work illustrating the validity of a PBPK modelling and simulation approach in 31 
predicting trends in oral drug exposure pre- to post-RYGB. 32 
33 
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Introduction 34 
Over the last decades, the prevalence of obesity has increased dramatically [1]. This has led to an increased demand for 35 
bariatric surgery, especially Roux-en-Y gastric bypass (RYGB), which is the only available treatment leading to major and 36 
sustainable weight reduction in morbid obese patients (BMI ≥ 40 kg/m² or BMI ≥ 35 kg/m² with obesity-related diseases) [2]. 37 
RYGB results in an altered anatomical structure of the gastrointestinal tract by reducing the gastric capacity and bypassing 38 
the duodenum and the proximal jejunum. Changes to the anatomical structure of the gastrointestinal tract following RYGB 39 
can alter the pharmacokinetics of a given drug by an increase in gastric pH (due to gastric resection and the widespread use of 40 
antacid medication following surgery), a delayed inlet of bile acids, a reduced small intestinal surface area available for 41 
absorption and a potential bypass of intestinal regions with high abundance of drug metabolising enzymes [3,4]. All of the 42 
above stated changes may impact oral drug absorption and bioavailability. However, the extent to which absorption is 43 
hampered for a specific drug, or class of drugs, remains unknown. The few studies that have been conducted illustrate that a 44 
trend in oral drug exposure before to after RYGB is not easy to predict. On the one hand, oral exposure can be reduced 45 
following RYGB, as reported for azithromycin [5]; on the other hand, it can remain unaltered, as reported for levothyroxine, 46 
or be increased, as for metformin [6,7]. A systematic approach to study the influence of RYGB on oral drug exposure is 47 
lacking as previously conducted studies vary in design and are poorly standardised based on how surgery is conducted, which 48 
makes the results difficult to compare.  49 
Drug substances can be classified according to their solubility and permeability, which forms the basic concept of the 50 
Biopharmaceutical Classification System (BCS) [8]. Based on its absorption characteristics, we have chosen to investigate 51 
the influence of RYGB on metoprolol, a BCS class I compound, which is characterized by a high solubility and high 52 
permeability. Metoprolol is a β1-blocker, and β-blockers are widely used cardiovascular drugs. Metoprolol (pKA = 9.18) is 53 
known to cross the intestinal mucosa by passive diffusion [9]. It is mainly metabolized by cytochrome P450 2D6 (CYP2D6) 54 
and in healthy volunteers, the half-life of metoprolol amounts to 3-4 h [10,11]. For the investigation of the influence of 55 
RYGB surgery on the disposition of metoprolol, we have chosen for an immediate release formulation and for a controlled 56 
release formulation; so far, controlled release formulations have never been studied in RYGB patients. It is generally advised 57 
to avoid formulations with a controlled release after bariatric surgery, but this advice is purely eminence based [12]. An 58 
additional aim of this study was to serve as an ongoing validation of a previously developed physiologically-based 59 
pharmacokinetic (PBPK) model [13] for predicting oral drug exposure following RYGB in order to validate its use for dose 60 
adjustments following surgery. This way, potential dangerous over- or underdosing of drugs can be avoided, which is 61 
especially a risk for drugs with a narrow therapeutic range.  62 
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Hence, this paper reports on two types of investigations: (1) evaluation of the oral pharmacokinetic parameters of metoprolol 63 
tartrate, a β1-blocker belonging to class I of the BCS (high solubility/high permeability), immediate and controlled release in 64 
obese patients before and after RYGB; (2) comparison of the in vivo data to the predictions from the PBPK modelling of 65 
metoprolol tartrate immediate and controlled release formulation before and after RYGB. 66 
67 
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Methods 68 
Selection of patients 69 
For this study (EudraCT number is 2012-001244-22), 14 obese patients with a planned RYGB surgery at the University 70 
Hospitals Leuven, Belgium, were recruited. Patients who had previously undergone bariatric surgery or who had renal and 71 
hepatic impairment were not included in the study. Pregnant and breastfeeding women were also not included. RYGB 72 
surgery was performed in all recruited patients by the same surgeon. In brief, the jejunum was divided 30 cm from the 73 
ligament of Treitz and anastomosed to a 30 mL proximal gastric pouch. The jejunum was reanastomosed 120 cm distally to 74 
the gastrojejunostomy. All mesenteric defects were closed. The study was approved by the Medical Ethics Committee of the 75 
University Hospitals Leuven (ML8433) and all patients gave written informed consent.  76 
Study design and procedure 77 
A single-dose pharmacokinetic study of metoprolol tartrate (referred to as metoprolol) 200 mg immediate release 78 
(Lopresor®) and controlled release (Slow-Lopresor®) was performed before and six to eight months after RYGB (on average 79 
6.6 months [SD 0.63]; further referred to as six months after RYGB). Both formulations were tested in all patients before and 80 
after RYGB, with an interval of at least 5 days between administration of the two formulations. The relative extent of oral 81 
exposure of metoprolol from both formulations was estimated by the determination of the area under the curve (AUC0-24h), 82 
the peak plasma concentration of metoprolol after oral administration (Cmax) and the time to reach peak concentration (Tmax). 83 
The AUC0-24h reflects drug absorption and drug elimination; in this paper we have mainly focused on drug absorption as a 84 
RYGB mainly influences the absorption through the formation of a gastric pouch and bypass of the proximal part of the small 85 
intestine.  86 
Following an overnight fast of at least 10 hours, subjects came to the clinical pharmacology unit of the University Hospitals 87 
Leuven. Weight and height of the subjects were measured with calibrated equipment. The weight was measured to the nearest 88 
0.1 kg, with the subjects having an emptied bladder and wearing indoor clothing with empty pockets and without shoes. BMI 89 
(kg/m²) was calculated by dividing the weight (kg) by the square of the height (m²). A Dual Energy X-ray Absorptiometry 90 
(DXA) was performed to measure the amount of body fat mass [14]. 91 
After the insertion of an intravenous catheter, the subjects ingested 200 mg of metoprolol (2 tablets of Lopresor® 100 mg or 92 
1 tablet of Slow-Lopresor® 200 mg) with 150 mL of water. The tablets were taken without being broken or crushed. After 93 
oral administration, blood samples were collected into heparinised tubes at 15; 30; 60; 90 minutes and 2; 2.5; 3; 3.5; 4; 5; 6; 94 
7; 8; 9; 10 and 24 hours. The blood samples were centrifuged immediately after collection (1800 g, 10 min, 4°C) and plasma 95 
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samples were stored at -20°C until analysis. At each time-point, the systolic blood pressure (SBP), diastolic blood pressure 96 
(DBP) and heart rate were determined with Omron, Model M6, Digital automatic blood pressure monitor, Intellisens
TM
. 97 
A standardised meal and a standardised snack were administered 4 hours and 8 hours after drug administration, respectively. 98 
Participants had to consume the entire meal. The use of water was allowed ad libitum, except for one hour before and four 99 
hours after drug administration. During the first 4 hours after administration of metoprolol, the patients had to remain semi-100 
supine in bed. After the 10h-blood sample, the subjects were discharged and they had to return the next morning for the 24-h 101 
blood sampling. As proton pump inhibitors, H2-receptor antagonists and antacids could influence the absorption of drugs, the 102 
recruited patients were asked to stop these drugs during the week preceding the study. Other prescription drugs were checked 103 
to verify that there were no pharmacokinetic interactions with the study drug. The morning of the study, the patients were not 104 
allowed to take their medication. 105 
All procedures were in accordance with the ethical standards of the Medical Ethics Committee of the University Hospitals 106 
Leuven.  107 
 108 
HPLC analysis 109 
The determination of the concentration of metoprolol was performed by a validated HPLC method with fluorescence 110 
detection (ex.271nm, em.302nm; Waters 2475 Multiwavelength Fluorescence Detector). Metoprolol was extracted after 111 
adding 1.25 mL of 0.2M HCl, 0.10 mL of 200 nM propranolol (as internal standard), 0.50 mL of 2M NaOH and 10.00 mL of 112 
CH2Cl2 to 0.50 mL of plasma by repeatedly vortexing. After extraction for one minute, it was centrifuged (4000 rpm, 10 min, 113 
4°C) and the supernatant was removed. The remaining organic solution was evaporated and the residue was dissolved in 114 
MeOH. This solution was evaporated again and resuspended in 0.15 mL of transport medium, which was injected into the 115 
HPLC system, equipped with an Alliance 2695 separations module and a Novapak C-18 column under radial compression 116 
(Waters, Milford, MA, USA). 117 
A gradient run was performed with 25 mM acetate buffer pH 3.5:methanol (51:49 v/v) during the first three minutes, 118 
followed by six minutes 25 mM acetate buffer pH 3.5:methanol (45:55 v/v). Then the column was rinsed with 119 
acetonitrile:water (90:10 v/v). The flow rate amounted to 1.10 mL/min resulting in a retention time of 4.2 min and 8.2 min 120 
for metoprolol and the internal standard, respectively.  121 
Calibration curves were made based on a stock solution of metoprolol in dimethyl sulfoxide and linearity was observed 122 
between 1337 ng/mL and 5 ng/mL. The intra-day accuracy and precision errors were 3.3% and 6.4%, respectively, for a 123 
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concentration of 535 ng/mL (corresponding to 2000 nM)  and 3.0% and 8.6%, respectively, for a concentration of 53 ng/mL 124 
(corresponding to 200 nM). The inter-day accuracy and precision errors were 6.1% and 1.0%, respectively, for a 125 
concentration of 535 ng/mL, and 4.8% and 3.5%, respectively, for a concentration of 53 ng/mL. 126 
Data and chapter analysis 127 
The AUC0-24h of the concentration-versus-time profiles was determined using the linear trapezoidal rule. Data are presented as 128 
mean (95% confidence interval, CI), unless otherwise mentioned. To evaluate the effect of RYGB on the pharmacokinetic 129 
parameters of metoprolol, AUC0-24h, Cmax and Tmax obtained before and after surgery were compared. The paired data were 130 
analysed with SPSS Statistics 22, performing a paired t-test as the assumption for normal distribution of the data was 131 
accepted (Shapiro-Wilk test). The AUC0-24h of the controlled release formulation was transformed with the logarithmic 132 
function to achieve normality. For the data analysis of Tmax, a Wilcoxon signed-rank test was performed as normality was not 133 
achieved. Multiple linear regression analysis was performed to control for confounding factors betweenthe difference inoral 134 
exposure of metoprolol and: gender, age, BMI, fat percentage as measured by DXA, weight loss, systolic and diastolic blood 135 
pressure and heart rate were included. No significant confounding factors were identified for AUC0-24h; so no adjustments for 136 
these factors were made. To compare the baseline pharmacodynamic parameters a paired t-test was performed, and the 137 
comparison of the pharmacodynamic profiles was carried out using a linear mixed model. Statistical significance was set at 138 
p<0.05.  139 
Physiologically-based pharmacokinetic modelling and simulation 140 
PBPK modelling and simulation was employed using the previously developed and validated RYGB PBPK absorption 141 
model, based on the obesity model by Ghobadi et al. (2011) available in the Simcyp Simulator, considering obesity related 142 
changes in drug disposition [15]. The RYGB PBPK absorption model was coupled to the minimal PBPK model incorporated 143 
into the Simcyp Simulator version 13.1, in order to elucidate the potential mechanism behind the observed trend in oral drug 144 
exposure of metoprolol immediate and controlled release formulation before to after RYGB [13,16,17]. Metoprolol 145 
immediate and controlled release compound files were developed based on the pre-validated metoprolol compound as 146 
supplied in the Simcyp compound library. Distributional parameters describing a two-compartmental distribution behaviour 147 
(Vss, Vsac, kin, kout) were estimated based on intravenous data from Regardh et al. [18] using the parameter estimation toolbox, 148 
obtaining the following estimates: 2.58 L/kg, 1.89 L/kg, 5.75 h
-1
 and 5.09 h
-1
 for Vss, Vsac, kin and kout, respectively. 149 
Clearances via cytochrome P450 isoforms 3A4 and 2D6 were estimated using the retrograde model, back-calculating 150 
intrinsic clearance (CLint) from intravenous clearance assuming a 7% contribution by CYP3A4 (Simcyp Simulator v13.1). In 151 
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vitro release profiles of metoprolol immediate and controlled release formulations were obtained from Oosterhuis et al. [19] 152 
and Polli et al. [20] and were fitted to a Weibull function using Matlab R2012a (Mathworks, Natick, MA, USA). For the 153 
immediate release metoprolol formulation the Weibull function describing the dissolution profile derived from simulated 154 
gastric fluid was directly implemented into the Simcyp Simulator. Dissolution of the controlled release formulation was 155 
scaled by in vitro-in vivo correlation (IVIVC) based on fast, medium and slow extended release profiles and plasma 156 
concentration-time data as reported by Eddington et al. [21]. The IVIVC produced a correction factor of 0.93 using the 157 
module in Simcyp Simulator v13.1. The RYGB absorption model was adapted as per Darwich et al. [16] in order to account 158 
for population-specific demographics (body weight, height, age and gender) pre and post RYGB, and surgical dimensions. 159 
Furthermore, oral bioavailability (Foral) was calculated using the following equation:  160 
Foral = FA * FG * FH 161 
where FA stands for fraction of drug absorbed; FG is the fraction of drug escaping gut wall metabolism and FH stands for the 162 
fraction of drug entering the portal vein escaping first pass metabolism in the liver. 163 
164 
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Results  165 
In this study, we recruited 14 patients (10 women, 4 men) with a mean age of 44.4 years (95% CI [38.0, 50.7]). The main 166 
characteristics of the participants are shown in Table 1. 167 
The observed and predicted pharmacokinetic data are summarised in Table 2 and the observed concentration-time profiles are 168 
shown in Fig. 1.  169 
 170 
[Insert Table 1] 171 
[Insert Table 2] 172 
[Insert Figure 1] 173 
 174 
The AUC0-24h of metoprolol immediate release was 32.4% (95% CI [1.36, 63.5]) higher 6 months following RYGB than 175 
before surgery. However, this difference was not statistically significant (paired t-test: p=0.07). Cmax for metoprolol 176 
immediate release tended to be 29.0% (95% CI [-1.86, 59.8]) higher after RYGB, but this difference did not reach statistical 177 
significance (paired t-test: p=0.07). The time to reach maximum plasma concentration was also not statistically significant 178 
different, but with a trend of Tmax being shorter after the operation: Tmax decreased from 1.36 h (95% CI [1.03, 1.69]) to 1.25 h 179 
(95% CI [0.89, 1.61]) (Wilcoxon: p=0.68). These trends were similar to the predicted data from the PBPK simulation and 180 
modelling: AUC0-24h and Cmax were also higher after RYGB by 16.0% and 34.0%, respectively; Tmax was shorter with a 181 
decrease from 1.72 h to 1.25 h after RYGB. The half-life increased from 4.2 h (95% CI [3.1, 5.3]) before RYGB to 4.9 h 182 
(95% CI [3.2, 6.6]) after RYGB; this difference was not significant.  183 
After administration of the metoprolol controlled release formulation, no statistically significant difference in AUC0-24h of 184 
metoprolol was observed, although a tendency towards increased oral exposure could be observed after RYGB as the AUC0-185 
24h after oral administration of the controlled release formulation was 55.9% (95% CI [5.73, 106]) higher than before RYGB 186 
(paired t-test: p=0.30). The same observation was made for the predicted data. In Fig. 2 the data from the in vivo 187 
pharmacokinetic study and the predicted data for metoprolol immediate and controlled release before and after RYGB are 188 
shown along with the segmental fraction of dose absorbed along the small intestine.  189 
[Insert Figure 2] 190 
[Insert Table 3] 191 
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In the simulated data, a very small reduction of 3 % in oral bioavailability (Foral) following RYGB was predicted (see Table 192 
3). 193 
During the pharmacokinetic study, pharmacodynamic parameters were also monitored (Fig. 3). Before administration of the 194 
metoprolol immediate release formulation, baseline systolic blood pressure (p=0.02) and heart rate (p=0.00) were 195 
significantly lower after RYGB; before administration of metoprolol controlled release, baseline systolic blood pressure 196 
(p=0.01) was significantly lower after RYGB. After administration of metoprolol immediate release, there was a significant 197 
interaction between time-point after administration and moment of the experiment (before or after surgery) for heart rate 198 
(p=0.029) and systolic blood pressure (p<0.001), but not for diastolic blood pressure. After administration of the controlled 199 
release formulation, there were no significant interaction effects regarding the pharmacodynamic parameters. 200 
[Insert Figure 3] 201 
202 
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Discussion 203 
As the knowledge regarding the impact of gastric bypass on drug disposition is very limited, this study aimed to investigate 204 
the disposition of BCS class I compound metoprolol from an immediate and controlled release formulation before and after 205 
RYGB, which would also serve as further validation of a previously developed RYGB PBPK absorption model. No 206 
significant differences were observed in the pharmacokinetic parameters of disposition of both formulations.  207 
Metoprolol (pKA = 9.18) is known to cross the intestinal mucosa through passive diffusion [9]. As this compound has a high 208 
solubility and high permeability [8,22], its absorption is not expected to be altered significantly after RYGB, which was 209 
indeed confirmed in this study.  210 
, despite the observed tendency towards a higher oral drug exposure.  211 
Besides its high solubility (>700 mg metoprolol tartrate/mL in water at 37°C) and high permeability, the absorption of 212 
metoprolol by the gastrointestinal tract is rapid and complete; no site dependent absorption occurs over a large part of the 213 
intestine [22,23]. However, in view of the reduced length of the gastrointestinal tract after RYGB, the absorption may be 214 
decreased. Additionally, surgery associated weight loss might result in a reduced distribution volume, which therefore may 215 
compensate for a possible reduction in oral absorption postoperatively. In a previous study in obese patients, the apparent 216 
distribution volume for metoprolol was shown to be higher in obese patients compared to non-obese patients with a lower 217 
peak concentration [24]. This can also contribute to the tendency towards an increased oral exposure post-RYGB, since the 218 
BMI and fat percentage is decreased six months post-RYGB compared to baseline. 219 
Furthermore, metoprolol undergoes metabolism in the liver by CYP2D6 and to a small extent by CYP3A4, resulting in the 220 
formation of metabolites (O-desmethylmetoprolol and α-hydroxymetoprolol) without a significant beta-blocking effect, [25]. 221 
As no significant changes were observed in the pharmacokinetic parameters of disposition and the half-life of metoprolol 222 
before and after surgery, CYP2D6 metabolism is probably the same before and after RYGB as metoprolol is a validated 223 
probe drug for CYP2D6 activity [26].  Also for the controlled release formulation, no significant differences in the 224 
disposition of metoprolol were observed. Both formulations contained the same salt, metoprolol tartrate, and we could 225 
therefore expect these two formulations to display the same solubility properties. Previous studies have shown that the extent 226 
of absorption of metoprolol is comparable along the gastrointestinal tract [27,28]. This may explain the absence of an effect 227 
on AUC0-24h for the controlled release formulation before and after RYGB as the absorption in more distal parts of the 228 
intestine can compensate for the bypassed proximal segment of the small intestine. Furthermore, for a controlled release 229 
formulation based on a matrix system, as is the case here, the intestinal transit time becomes an important factor in limiting 230 
absorption. In only a few studies the intestinal transit time after RYGB has been investigated. Dirksen et al. have shown that 231 
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the small intestinal transit time after a meal was slower in patients more than one year post-RYGB than in control subjects, 232 
while the colonic transit rate did not differ between the groups [29]. These observations do not entirely correspond with the 233 
findings of Morinigo et al., who have shown that the oro-caecal transit time, which includes pouch emptying and small 234 
intestinal transit, was shorter in RYGB-patients. Other studies have already shown that the gastric emptying for liquids is 235 
accelerated after RYGB [30-32]. Carswell et al. also reported on the oro-caecal transit time using sulphasalazine; in this 236 
study, RYGB had no impact on the oro-caecal transit time [33]. Overall, these studies indicate that the transit time before and 237 
after RYGB is probably comparable, which contributes to the similar disposition of metoprolol after administration of the 238 
controlled release formulation. Although, the oral exposure after administration of the controlled release formulation had also 239 
the tendency to be increased; this might be explained by the characteristics of the compound, as discussed for the immediate 240 
release formulation. 241 
Because it is impossible to test all the drugs on the market in clinical trials in specific patient populations, PBPK modelling 242 
may be considered a complimentary approach in that it may provide potential insights as to what factors are mainly 243 
responsible for observed differences in drug exposure between populations. During the last few years, PBPK modelling has 244 
indeed seen an expanding area of applications, including that of post bariatric surgery patients. A pharmacokinetic model was 245 
created for the different types of bariatric surgery, including RYGB, by Darwich et al [13]. The observed data of metoprolol 246 
immediate and controlled release were compared to matched simulations utilising the PBPK RYGB model. The trends 247 
observed in the clinical studies were comparable to the predictions made using the PBPK modelling and simulation approach. 248 
However, an overprediction occurred in the first part of the concentration-time profiles, especially for the slow release 249 
formulation which could probably be attributed to the lack of well-established in-vitro in-vivo correlation methods. Despite 250 
this minor overprediction, the observed data were well within the 95% prediction intervals. According to simulations, the 251 
trend of an increased oral exposure was mainly due to weight loss as the oral bioavailability remained almost constant before 252 
and after surgery. For the observed data, weight loss could contribute to the tendency of the increased exposure of metoprolol 253 
post-RYGB.  254 
Based on the current results one could conclude that the PBPK modelling and simulation provides a good platform for 255 
reasoning around what factors will be the most significant in determining the disposition of metoprolol following RYGB. 256 
As already mentioned, metoprolol is metabolized by CYP2D6, which has a genetic heterogeneity; a different CYP2D6 257 
genotype and metabolizer phenotype may thus influence the pharmacokinetics of metoprolol [11,34]. Therefore, it may be 258 
advantageous to determine the genotype of the volunteers, which was not performed in this study. However, the fact that we 259 
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followed the same group before and after the operation (i.e. the genotype in both groups was the same) rules out the absolute 260 
necessity of genotyping.   261 
It also has to be kept in mind that the expression of cytochrome P450 enzymes is the highest in duodenum and jejunum and 262 
decreases towards to more distal sites of the small intestine [35]; bypassing parts of the proximal small intestine with a high 263 
abundance of CYP enzymes may therefore lead to a different effect on the bioavailability of drugs metabolized by CYP 264 
enzymes, depending on the genotype. Bypassing first-pass metabolism in the proximal small intestine may also contribute to 265 
the tendency of an increased exposure of metoprolol after RYGB as it results in a decreased presystemic biotransformation. 266 
A similar effect has been described by Skottheim et al. [36] concerning the exposure of atorvastatin following gastric bypass 267 
surgery. 268 
In this study, we also explored the influence of both formulations on the pharmacodynamic parameters; the blood pressure 269 
and heart rate at baseline were lower after the operation. This can be explained by the improvement of cardiovascular 270 
parameters after RYGB [37].  271 
Overall, the strength of this study lies in the fact that it was performed in the same patient group before and after the 272 
operation, and that the same type of surgery was performed by the same surgeon. This design helps to minimize inter-273 
individual differences in metoprolol exposure before and after surgery, which is important as there are several factors 274 
contributing to the inter-individual variability in the pharmacokinetics of metoprolol (such as age, first-pass metabolism and 275 
intestinal absorption) [9].  276 
In the future, more challenging drugs will be studied, including low solubility compounds for which solubilisation depends 277 
on intraluminal bile salt concentrations or on the residence time in the acidic environment of the stomach.  278 
To conclude, the oral exposure of metoprolol immediate release and controlled release formulation was not significantly 279 
different before compared to after RYGB, although a tendency towards higher exposure existed following surgery, which 280 
could be explained by weight loss and a reduced presystemic biotransformation in the proximal GI-tract. The PBPK 281 
modelling and simulation predicted values were similar to the observed data, confirming its validity in daily clinical practice   282 
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Table legends 
Table 1 Characteristics of the participants, shown as mean (95% CI). 
Table 2 Pharmacokinetic results and predicted results for the immediate (IR) and controlled release (CR) 
formulation of metoprolol before and after surgery. 
Table 3 Predicted results for the bioavailability of metoprolol.  FA,
 
fraction of drug absorbed; FG, fraction of drug 
escaped gut metabolism; FH, fraction escaped first pass metabolism; Foral, oral bioavailability. 
 
Figure legends 
Fig. 1 Observed plasma concentration-time profiles of metoprolol over 24h after the administration of an 
immediate release dosage form before and after RYGB (A) and a controlled release dosage form before and after 
RYGB (B), shown as mean concentration±sem (n=14). 
 
Fig. 2 Mean plasma concentration-time profiles from the in vivo pharmacokinetic study and predicted mean 
plasma concentration-time profiles over 24h for the immediate release (A) and controlled release formulation (B) 
and predicted mean of segmental fraction of dose absorbed along the intestine for immediate release (C) and 
controlled release formulation (D).  
 
Fig. 3 Pharmacodynamic parameters: systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart 
rate at the different time-points after administration of the immediate formulation (A and B) and controlled 
release formulation (C and D), shown as mean concentration±SD. 
 
 
 
 
 
 
